Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048
Under a Creative Commons license
open access
Keywords
Phase III clinical trial
Chemotherapy head and neck neoplasms
Immunotherapy
Patient reported outcome measures
Pembrolizumab
Quality of life
Squamous cell carcinoma of head and neck
Cited by (0)
© 2022 Merck Sharp & Dohme Corp., a subsidiary Merck & Co., Inc., Kenilworth, NJ, USA and The Author(s). Published by Elsevier Ltd.